Your session is about to expire
← Back to Search
[18F] F-GLN PET/CT Imaging for Breast Cancer ([18F]F-GLN Trial)
[18F]F-GLN Trial Summary
This trial is for patients with breast cancer who have one lesion that is 1.5 cm in diameter or greater. Patients must be at least 18 years old to participate. up to 40 subjects will be observed in this study, with 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC) being given priority. [18F]F-GLN PET/CT will not be used to make treatment decisions, but to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. The safety of [18F]F-GLN will
[18F]F-GLN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria below[18F]F-GLN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.[18F]F-GLN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have any health issues that a doctor thinks would make the study unsafe for me.I have or might have breast cancer that has spread.I am not pregnant or breastfeeding.I have a tumor larger than 1.5 cm visible on an imaging test.I am 18 years old or older.
- Group 1: UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is enrollment increasing for this research project?
"Affirmative. The information displayed on clinicaltrials.gov confirms that this research is still recruiting participants, with a commencement date of April 5th 2019 and an amendment made July 5th 2022. 30 individuals will be needed to complete the study at one site."
Is access to this trial currently available for individuals?
"Affirmative. Clinicaltrials.gov data proclaims that this research initiative, which was initially published on April 5th 2019, is still actively recruiting participants. Approximately 30 patients need to be enrolled from 1 trial centre."
Has Fluoroglutamine [18F]F-GLN been officially acknowledged by the FDA?
"Due to the early stage of development, our team at Power has assigned Fluoroglutamine [18F]F-GLN a score of 1 on the safety scale. This is because Phase 1 trials typically have limited data available with regard to both efficacy and security."
Share this study with friends
Copy Link
Messenger